Horizon Pharma plc Announces Leading Proxy Advisory Service, Glass Lewis & Co., Recommends Depomed Shareholders Provide Consent FOR the Two Special Meeting Requests - Seite 2

• "has expressed willingness to pay a portion of the merger consideration in cash and appears generally willing to work with [Depomed] to explore mutually acceptable offer conditions, within reasonable limits, in [Glass Lewis's] view."
• "[has] provide[d] a detailed case regarding the potential strategic benefits of a merger" and said it "believe[s] [Depomed] shareholders should have the opportunity to more carefully consider the potential transaction [with Horizon Pharma], which, prima facie, appears to have some merit."

"We are pleased that both ISS and Glass Lewis have now affirmed that Depomed shareholders deserve the opportunity to have their voices heard and support the calling of the two related special meetings," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. "It is time for Depomed shareholders to protect their interests and provide consent FOR the calling of the two related special meetings we are requesting."

As expected, Glass Lewis did not at this juncture take a position on how shareholders should vote at the special meetings.

As previously noted in an open letter to Depomed shareholders, filed by Horizon Pharma on September 25, 2015 with the Securities and Exchange Commission, Horizon Pharma has established September 30, 2015 as an informal target date for Depomed shareholders to submit proxy cards and/or voting instruction forms for the calling of the Removal and Bylaw Amendments Special Meeting and the Election Special Meeting. September 30, 2015 is an informal target date as Depomed shareholders will be able to submit proxies/voting instruction forms and/or revoke proxies/voting instruction forms until Horizon Pharma submits special meeting requests to Depomed and exercises the proxies it receives to do so.

Horizon Pharma's solicitation statement for calling the two related special meetings and the letter to Depomed shareholders from Horizon Pharma describing the reasons Depomed shareholders should support the solicitation to call the special meetings, along with the documents related to Horizon Pharma's concurrent exchange offer for all of the outstanding shares of Depomed common stock, are viewable at: www.HorizonAndDepomed.com, a website that Horizon Pharma launched to provide details and other relevant information regarding its proposals for the special meetings and its proposed acquisition of Depomed via the exchange offer.